These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10940919)

  • 1. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif.
    Bourgault Villada I; Bénéton N; Bony C; Connan F; Monsonego J; Bianchi A; Saiag P; Lévy JP; Guillet JG; Choppin J
    Eur J Immunol; 2000 Aug; 30(8):2281-9. PubMed ID: 10940919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
    J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
    Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
    Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
    Castellanos MR; Hayes RL; Maiman MA
    Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
    Bauer M; Wagner H; Lipford GB
    Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.
    Evans M; Borysiewicz LK; Evans AS; Rowe M; Jones M; Gileadi U; Cerundolo V; Man S
    J Immunol; 2001 Nov; 167(9):5420-8. PubMed ID: 11673561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.
    Bauer S; Heeg K; Wagner H; Lipford GB
    Scand J Immunol; 1995 Sep; 42(3):317-23. PubMed ID: 7660065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
    Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
    Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions.
    Peng S; Trimble C; Wu L; Pardoll D; Roden R; Hung CF; Wu TC
    Clin Cancer Res; 2007 Apr; 13(8):2479-87. PubMed ID: 17438108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
    Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
    Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
    Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
    Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.
    Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL
    J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.
    Nakagawa M; Kim KH; Moscicki AB
    Clin Diagn Lab Immunol; 2004 Sep; 11(5):889-96. PubMed ID: 15358648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
    Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
    J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.
    Sadovnikova E; Zhu X; Collins SM; Zhou J; Vousden K; Crawford L; Beverley P; Stauss HJ
    Int Immunol; 1994 Feb; 6(2):289-96. PubMed ID: 7512375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
    Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.